论文部分内容阅读
目的评价低分子肝素治疗不稳定性心绞痛的疗效及其安全性。方法将不稳定性心绞痛患者64例随机分为两组:低分子肝素组34例,对照组30例。低分子肝素组:给予低分子肝素5000IU/次,每日2次皮下注射,连续应用1周;常规肝素组:给予肝素100mg/次,每日2次静点。监测心绞痛发生情况、心电图、出凝血时间、副作用及不良反应。结果低分子肝素对不稳定性心绞痛具有较好疗效,其总有效率为91.2%,常规肝素总有效率为76.6%,两组相比具有差异(P<0.05)。两组均无显著出血,低分子肝素组局部出血副作用少于普通肝素组,具有差异。结论低分子肝素皮下注射治疗不稳定性心绞痛疗效确切、安全、方便,无明显不良反应,可作为不稳定性心绞痛常规治疗。
Objective To evaluate the efficacy and safety of low molecular weight heparin in the treatment of unstable angina pectoris. Methods 64 patients with unstable angina were randomly divided into two groups: low molecular weight heparin group of 34 patients and control group of 30 patients. Low molecular weight heparin group: given low molecular weight heparin 5000IU / times, twice daily subcutaneous injection, continuous application for 1 week; conventional heparin group: given heparin 100mg / times, 2 times a day static point. Monitoring angina pectoris, ECG, clotting time, side effects and adverse reactions. Results Low molecular weight heparin had a good effect on unstable angina pectoris. The total effective rate was 91.2%. The total effective rate of conventional heparin was 76.6%. There was significant difference between the two groups (P <0.05). No significant bleeding in both groups, low molecular weight heparin group of local bleeding less than unfractionated heparin group, with differences. Conclusion Low molecular weight heparin subcutaneous injection of unstable angina pectoris is effective, safe, convenient and without obvious adverse reactions, which can be used as routine treatment of unstable angina pectoris.